Breaking News

Over a quarter ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: After-Hours Movers » 18:30
03/14/22
03/14
18:30
03/14/22
18:30
ID

Parts iD

$1.79 /

-0.03 (-1.65%)

, GTLB

GitLab

$33.20 /

-2.24 (-6.32%)

, CANO

Cano Health

$5.44 /

-0.475 (-8.03%)

, YALA

Yalla

$3.70 /

-0.66 (-15.14%)

, WPRT

Westport

$1.36 /

-0.1 (-6.87%)

, COUP

Coupa Software

$89.81 /

-9.48 (-9.55%)

, DLO

dLocal

$23.40 /

-1.03 (-4.22%)

, LIFE

aTyr Pharma

$4.75 /

-0.5 (-9.52%)

, ANAB

AnaptysBio

$28.53 /

-0.45 (-1.55%)

, EXEL

Exelixis

$20.59 /

-0.415 (-1.98%)

Check out this evening's…

ShowHide Related Items >><<
YALA Yalla
$3.70 /

-0.66 (-15.14%)

WPRT Westport
$1.36 /

-0.1 (-6.87%)

LIFE aTyr Pharma
$4.75 /

-0.5 (-9.52%)

ID Parts iD
$1.79 /

-0.03 (-1.65%)

GTLB GitLab
$33.20 /

-2.24 (-6.32%)

EXEL Exelixis
$20.59 /

-0.415 (-1.98%)

COUP Coupa Software
$89.81 /

-9.48 (-9.55%)

CANO Cano Health
$5.44 /

-0.475 (-8.03%)

ANAB AnaptysBio
$28.53 /

-0.45 (-1.55%)

ID Parts iD
$1.79 /

-0.03 (-1.65%)

11/10/21 DA Davidson
Parts iD downgraded to Neutral at DA Davidson after Q3 sales miss
11/10/21 Canaccord
Parts iD price target lowered to $8 from $12 at Canaccord
11/10/21 DA Davidson
Parts iD downgraded to Neutral from Buy at DA Davidson
06/15/21 Canaccord
Parts iD platform key differentiator in largely offline industry, says Canaccord
GTLB GitLab
$33.20 /

-2.24 (-6.32%)

03/14/22 RBC Capital
GitLab price target lowered to $60 from $90 at RBC Capital
02/04/22 RBC Capital
GitLab upgraded to Outperform from at RBC Capital on valuation
02/04/22 RBC Capital
GitLab upgraded to Outperform from Sector Perform at RBC Capital
01/27/22 JPMorgan
JPMorgan upgrades 'Growth All-Star' GitLab to Overweight
CANO Cano Health
$5.44 /

-0.475 (-8.03%)

03/10/22 Citi
Citi sees potential for Cano Health buyout near $12 per share
02/17/22 Citi
Citi opens 'negative catalyst watches' in health care services
01/10/22 Citi
Cano Health assumed with a Buy at Citi
12/07/21 Cowen
Cano Health price target lowered to $15 from $18 at Cowen
YALA Yalla
$3.70 /

-0.66 (-15.14%)

08/10/21 Oppenheimer
Yalla price target lowered to $25 from $30 at Oppenheimer
WPRT Westport
$1.36 /

-0.1 (-6.87%)

02/08/22 H.C. Wainwright
Westport price target lowered to $12 from $16 at H.C. Wainwright
02/07/22 Craig-Hallum
Westport looking 'far too cheap,' says Craig-Hallum
11/09/21 Lake Street
Lake Street still bullish on Westport despite Q3 shortfall on supply chain woes
09/09/21 JPMorgan
Westport initiated with a Neutral at JPMorgan
COUP Coupa Software
$89.81 /

-9.48 (-9.55%)

03/08/22 UBS
Coupa Software price target lowered to $130 from $208 at UBS
03/01/22 KeyBanc
Coupa Software price target lowered to $175 from $200 at KeyBanc
02/23/22 Mizuho
Coupa Software price target lowered to $130 from $180 at Mizuho
01/31/22 BMO Capital
Coupa Software initiated at Market Perform at BMO with set-up 'difficult'
DLO dLocal
$23.40 /

-1.03 (-4.22%)

02/10/22 UBS
dLocal upgraded to Buy at UBS on 'attractive valuation'
02/10/22 UBS
dLocal upgraded to Buy from Neutral at UBS
01/31/22 HSBC
dLocal upgraded to Buy from Hold at HSBC
01/26/22 Goldman Sachs
dLocal upgraded to Buy from Neutral at Goldman Sachs
LIFE aTyr Pharma
$4.75 /

-0.5 (-9.52%)

11/11/21 Roth Capital
aTyr Pharma 2022 catalysts 'should be on your radar,' says Roth Capital
10/12/21 RBC Capital
aTyr Pharma initiated with an Outperform at RBC Capital
09/21/21 Piper Sandler
aTyr Pharma initiated with an Overweight at Piper Sandler
09/14/21 Oppenheimer
aTyr Pharma price target raised to $20 from $14 at Oppenheimer
ANAB AnaptysBio
$28.53 /

-0.45 (-1.55%)

03/07/22 H.C. Wainwright
AnaptysBio price target raised to $46 from $43 at H.C. Wainwright
11/15/21 H.C. Wainwright
AnaptysBio data show favorable safety profile, says H.C. Wainwright
10/26/21 Wedbush
AnaptysBio price target raised to $32 from $25 at Wedbush
08/18/21 Wedbush
AnaptysBio price target raised to $25 from $20 at Wedbush
EXEL Exelixis
$20.59 /

-0.415 (-1.98%)

03/14/22 Piper Sandler
Exelixis price target lowered to $30 from $34 at Piper Sandler
02/25/22 Jefferies
Court denied MSN motion to add patents to fight with Exelixis, says Jefferies
02/18/22 H.C. Wainwright
Exelixis price target lowered to $42 from $52 at H.C. Wainwright
02/18/22 Piper Sandler
Exelixis positioned for 'strong' 2022, says Piper Sandler
YALA Yalla
$3.70 /

-0.66 (-15.14%)

WPRT Westport
$1.36 /

-0.1 (-6.87%)

LIFE aTyr Pharma
$4.75 /

-0.5 (-9.52%)

ID Parts iD
$1.79 /

-0.03 (-1.65%)

GTLB GitLab
$33.20 /

-2.24 (-6.32%)

EXEL Exelixis
$20.59 /

-0.415 (-1.98%)

DLO dLocal
$23.40 /

-1.03 (-4.22%)

COUP Coupa Software
$89.81 /

-9.48 (-9.55%)

CANO Cano Health
$5.44 /

-0.475 (-8.03%)

ANAB AnaptysBio
$28.53 /

-0.45 (-1.55%)

  • 21
    Oct
  • 14
    Oct
  • 16
    Sep
  • 03
    Jun
  • 03
    Jun
GTLB GitLab
$33.20 /

-2.24 (-6.32%)

EXEL Exelixis
$20.59 /

-0.415 (-1.98%)

DLO dLocal
$23.40 /

-1.03 (-4.22%)

COUP Coupa Software
$89.81 /

-9.48 (-9.55%)

CANO Cano Health
$5.44 /

-0.475 (-8.03%)

WPRT Westport
$1.36 /

-0.1 (-6.87%)

LIFE aTyr Pharma
$4.75 /

-0.5 (-9.52%)

GTLB GitLab
$33.20 /

-2.24 (-6.32%)

DLO dLocal
$23.40 /

-1.03 (-4.22%)

COUP Coupa Software
$89.81 /

-9.48 (-9.55%)

CANO Cano Health
$5.44 /

-0.475 (-8.03%)

Earnings
Yalla reports Q4 EPS 16c vs. 15c last year » 17:14
03/14/22
03/14
17:14
03/14/22
17:14
YALA

Yalla

$3.70 /

-0.66 (-15.14%)

Reports Q4 revenue…

Reports Q4 revenue $67.6M, one estimate $71.3M. "2021 was a remarkable year for Yalla. We made tremendous progress in expanding our product portfolio, establishing an integrated ecosystem and elevating the rich diversity of our business and its services to new heights," said Mr. Yang Tao, Founder, Chairman and CEO of Yalla. "Of special note, we successfully launched the MENA region's first-ever social metaverse app, WAHA, enabling our users to enjoy immersive, 3D social scenes. We also recently released YallaChat version 0.3, iterating our IM product with new features tailored to MENA's local user preferences. Moreover, our game distribution business progressed smoothly, with investments in mid-core to hard-core game projects. As always, we strive to broaden our product range through diverse developments, investments and collaborations devoted to fulfilling MENA users' evolving online social networking and entertainment needs."

ShowHide Related Items >><<
YALA Yalla
$3.70 /

-0.66 (-15.14%)

YALA Yalla
$3.70 /

-0.66 (-15.14%)

08/10/21 Oppenheimer
Yalla price target lowered to $25 from $30 at Oppenheimer
Hot Stocks
Yalla announces dismissal of securities class action lawsuit » 18:02
01/19/22
01/19
18:02
01/19/22
18:02
YALA

Yalla

$6.20 /

+0.155 (+2.57%)

Yalla Group announced…

Yalla Group announced that the lead plaintiffs in a securities class action lawsuit against the company and its CEO voluntarily dismissed the lawsuit on January 12, which marks a successful and final conclusion of the lawsuit for the company. The lawsuit arose from certain short-seller reports issued in May 2021 that contained numerous errors as well as distorted, misleading and unsubstantiated claims regarding the company. While the company publicly refuted the claims in the short-seller reports, a putative securities class action lawsuit was filed against the company and its CEO in the United States based on the claims in the short-seller reports, claiming that the company had violated U.S. securities laws. The U.S. court presiding over this lawsuit ordered the lead plaintiffs and their attorneys to file an amended complaint by January 7. After several months of preparation, the lead plaintiffs and their attorneys failed to file an amended complaint by the deadline set by the court. Instead, the lead plaintiffs and their attorneys elected not to further pursue this lawsuit and voluntarily dismissed the lawsuit on January 12, agreeing to bear their own litigation costs. Lead plaintiffs are barred from refiling the same claims. The voluntary dismissal equally applies to all claims asserted against the company's CEO, who was named a co-defendant in the lawsuit. The court approved the lead plaintiffs' voluntary dismissal on January 13, and the lawsuit is terminated. Throughout the process, the company maintained that the lawsuit had no factual basis. The company believes the decision of the lead plaintiffs and their attorneys to voluntarily dismiss all of their claims after several months of preparation supports the company's position that claims in the short-seller reports are groundless.

ShowHide Related Items >><<
YALA Yalla
$6.20 /

+0.155 (+2.57%)

YALA Yalla
$6.20 /

+0.155 (+2.57%)

08/10/21 Oppenheimer
Yalla price target lowered to $25 from $30 at Oppenheimer
03/12/21 Oppenheimer
Yalla upgraded to Outperform from Perform at Oppenheimer
03/12/21 Oppenheimer
Yalla upgraded to Outperform from Perform at Oppenheimer
YALA Yalla
$6.20 /

+0.155 (+2.57%)

Hot Stocks
Yalla rises 13.5% » 12:00
11/15/21
11/15
12:00
11/15/21
12:00
YALA

Yalla

$9.46 /

+1.11 (+13.29%)

Yalla is up 13.5%, or…

Yalla is up 13.5%, or $1.13 to $9.51.

ShowHide Related Items >><<
YALA Yalla
$9.46 /

+1.11 (+13.29%)

YALA Yalla
$9.46 /

+1.11 (+13.29%)

08/10/21 Oppenheimer
Yalla price target lowered to $25 from $30 at Oppenheimer
03/12/21 Oppenheimer
Yalla upgraded to Outperform from Perform at Oppenheimer
03/12/21 Oppenheimer
Yalla upgraded to Outperform from Perform at Oppenheimer
12/10/20 Oppenheimer
Yalla initiated with a Perform on valuation at Oppenheimer
YALA Yalla
$9.46 /

+1.11 (+13.29%)

YALA Yalla
$9.46 /

+1.11 (+13.29%)

YALA Yalla
$9.46 /

+1.11 (+13.29%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.